25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.
November 2024 in “Circulation” This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.
September 2025 in “Turkish Journal of Dermatology” This study found that children with alopecia areata had higher levels of oxidative stress markers but showed no significant differences in depression and suicide tendencies compared to healthy peers.
March 2025 in “Journal of Cosmetic Dermatology” This study found that reports of suicidal ideations linked to oral finasteride were significantly higher in 2013–2018 and 2019–2023 compared to 2006–2011, potentially due to increased awareness of post-finasteride syndrome from 2012 onward. No such signals were seen with oral dutasteride.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.